VIP (guinea pig)


  • Description

  • Application Data


Vasoactive intestinal peptide (VIP) is a neuropeptide involved in neurotransmission and smooth muscle relaxation.

See full description

Application Data

Catalogue number crb1001039
Molecular Weight 3342.7
Sequence (one letter code)


Sequence (three letter code)


Aliase gp VIP
Purity >95%
cas 96886-24-7
Storage -20°C

Törnwall et al., (1994). Distribution of vasoactive intestinal peptide (VIP) and its binding sites in labial salivary glands in Sjögren’s syndrome. Clin. Exp. Rheumatol., 12: 287.


Atas et al., (2021). Changes in ghrelin, substance P and vasoactive intestinal peptide levels in the gastroduodenal mucosa of patients with morbid obesity. Neuropeptides, 89: 102164. doi: 10.1016/j.npep.2021.102164.

Iwasaki M et al., (2019). Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. Faculty Rev., F1000(8): 1629. PMID: 31559013.

Manufactured in: United Kingdom
Material Safety Data Sheet (MSDS)

Vasoactive intestinal peptide (VIP) is a neuropeptide found throughout the body and the central nervous system. VIP is located within cell bodies and nerve endings of the enteric nervous system, brain and pancreas. VIP neurons in the peripheral system fire to regulate blood vessels, and the  CNS innervate cerebral vasculature. VIP  binds to G protein-coupled receptors VPAC1 and VPAC2. VIP and VPAC2 are detected in circular smooth muscle cells of cerebral arterioles. VIP and VPAC1 are also found in lymphatic tissue. VIP can block inflammation, modify the Th response favouring Th2 and induce regulatory T cells. Overexpression of each receptor has been linked to various cancers.

VIP administration leads to pancreatic bicarbonate-rich fluid secretion but not to the same degree stimulated by secretin. VIP stimulates insulin secretion in a glucose-dependent manner and also stimulates glucagon secretion. Studies have found that in morbidly obese patients, VIP levels are lowered and work to slow gastric and duodenal motility but increase gastric emptying. Therefore, decreasing VIP levels in obese patients may increase weight gain by accelerating gastric emptying.

VIP has been well studied in pancreatic acini. VIP is a full agonist of amylase secretion and increases cyclic AMP synchronised with an increase in intracellular Ca2+ triggered by stimuli that act through cholecystokinin (CCK) or cholinergic agonists. Most cAMP increases and amylase secretion appears to be mediated via VPAC1.

VIP (guinea pig)

Cat No.Pack SizePriceQty.
Bulk Quote

You may also like…